Dec 12 (Reuters) – Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their experimental cancer drug combination in patients with advanced stomach and esophageal cancers after it failed to show a survival benefit.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Anil D’Silva)
Comments